Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791816 · ClinicalTrials.gov registry record · Early Phase 1
Mechanisms of Vasovagal Syncope
A Early Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT01791816: Completed Early Phase 1 study, sponsored by New York Medical College.
NCT01791816 is a Early Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 90 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01791816, a Early Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Together they afflict many Americans, mostly young women, who are prevented from gainful employ or school attendance. The underlying mechanism is not known. Our past work suggests that a simple molecule, nitric oxide, acts to subvert normal blood flow controls causing blood to pool in the gut when standing. Our proposal will show the mechanism behind this problem and will indicate effective medical treatments. Patients will be compared to healthy control subjects.
Interventions
- DRUG Phenylephrine
- DRUG L-Ng-monomethyl Arginine (L-NMMA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-02 |
| Est. Completion | 2022-12 |
| Phase | Early Phase 1 |
What the finished NCT01791816 record still lists
NCT01791816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 2 interventions - of which Phenylephrine is the first listed.
NCT01791816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01791816 about?
NCT01791816 is a clinical study titled "Mechanisms of Vasovagal Syncope". Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Together they afflict many Americans, mostly young women, who are prevented from gainful employ or schoo...
What is the current status of trial NCT01791816?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2013-02. Estimated completion is 2022-12.
What interventions are being tested in trial NCT01791816?
The interventions under investigation include: Phenylephrine (DRUG), L-Ng-monomethyl Arginine (L-NMMA) (DRUG).
Who is sponsoring clinical trial NCT01791816?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01791816's enrollment target sits among peer trials
90 233rd of 2000 higher than 1,753 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia